Connect Biopharma Holdings Ltd ADR (CNTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 06-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 7,709 | -8,693 | -59,383 | -29,272 | -114,151 |
| Depreciation Amortization | 476 | 164 | 988 | 485 | 996 |
| Accounts payable and accrued liabilities | -1,959 | -1,840 | N/A | N/A | N/A |
| Other Working Capital | -17,891 | 6,711 | 9,485 | -1,646 | 7,039 |
| Other Operating Activity | 3,691 | 3,067 | 980 | 614 | 8,528 |
| Operating Cash Flow | $-7,974 | $-591 | $-47,930 | $-29,819 | $-97,588 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 9,250 | N/A | N/A | N/A |
| PPE Investments | -436 | N/A | -294 | -274 | -4,210 |
| Sale Of Investment | 12,757 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -44 | 0 | 75,449 | 33,127 | -77,821 |
| Investing Cash Flow | $12,277 | $9,250 | $75,155 | $32,853 | $-82,031 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 102 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -148 | 0 | -246 | -125 | -90 |
| Financing Cash Flow | $-46 | $N/A | $-246 | $-125 | $-90 |
| Exchange Rate Effect | -90 | -221 | 18 | 2,546 | 13,640 |
| Beginning Cash Position | 106,007 | 105,663 | 79,010 | 76,154 | 245,079 |
| End Cash Position | 110,174 | 114,101 | 106,007 | 81,609 | 79,010 |
| Net Cash Flow | $4,167 | $8,438 | $26,997 | $5,455 | $-166,069 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,974 | -591 | -47,930 | -29,819 | -97,588 |
| Capital Expenditure | -436 | N/A | N/A | N/A | N/A |
| Free Cash Flow | -8,410 | -591 | -47,930 | -29,819 | -97,588 |